Printed from https://ideas.repec.org/s/spr/pharme5.html
Content
April 2018, Volume 36, Issue 4
- 505-505 Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
by Amir Ansaripour & Carin A. Uyl-de Groot & W. Ken Redekop - 507-507 Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal
by Irina A. Tikhonova & Tracey Jones-Hughes & James Dunham & Fiona C. Warren & Sophie Robinson & Peter Stephens & Martin Hoyle
March 2018, Volume 36, Issue 3
- 259-261 Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care
by Ya-Chen Tina Shih & Shelley Fuld Nasso & S. Yousuf Zafar - 263-284 Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions
by Paolo A. Cortesi & Lucia S. D’Angiolella & Alessandra Lafranconi & Mariangela Micale & Giancarlo Cesana & Lorenzo G. Mantovani - 285-288 Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Robert Wolff & Anoukh Giessen & Xavier Pouwels & Debra Fayter & Shona Lang & Nigel Armstrong & Gill Worthy & Steven Duffy & Jos Kleijnen & Manuela A. Joore - 289-299 Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & Ahmed Abdulla & Adrian Bagust & Sophie Beale & Marty Richardson & Angela Stainthorpe & Angela Boland & Eleanor Kotas & Joanne McEntee & Daniel Palmer - 301-322 Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review
by Lazaros Andronis & Ilias Goranitis & Sue Bayliss & Rui Duarte - 323-340 Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review
by Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek - 341-347 A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis
by Shijie Ren & Jonathan Minton & Sophie Whyte & Nicholas R. Latimer & Matt Stevenson - 349-358 Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis
by Rebekah Fong Soe Khioe & Chris Skedgel & Andrew Hart & Michael Philip Nelson Lewis & Leo Alexandre - 359-368 Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
by Amr Makady & Ard Veelen & Páll Jonsson & Owen Moseley & Anne D’Andon & Anthonius Boer & Hans Hillege & Olaf Klungel & Wim Goettsch - 369-380 Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases
by Margret V. Bjarnadottir & David Czerwinski & Eberechukwu Onukwugha - 381-382 Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
by Amir Ansaripour & Carin A. Uyl-de Groot & W. Ken Redekop - 383-384 Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”
by Noga Gershon & Yakir Berchenko
February 2018, Volume 36, Issue 2
- 127-130 Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines
by Salah Ghabri & Irina Cleemput & Jean-Michel Josselin - 131-144 Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Iñigo Bermejo & Matt Stevenson & Katy Cooper & Sue Harnan & Jean Hamilton & Mark Clowes & Christopher Carroll & Tim Harrison & Shironjit Saha - 145-159 Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
by Nasuh C. Büyükkaramikli & Saskia Groot & Debra Fayter & Robert Wolff & Nigel Armstrong & Lisa Stirk & Gill Worthy & Fernando Albuquerque de Almeida & Jos Kleijnen & Maiwenn J. Al - 161-173 The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
by Livia Lovato Pires de Lemos & Augusto Afonso Guerra Júnior & Marisa Santos & Carlos Magliano & Isabela Diniz & Kathiaja Souza & Ramon Gonçalves Pereira & Juliana Alvares & Brian Godman & Marion Bennie & Ivan Ricardo Zimmermann & Vânia Crisitna Canuto Santos & Clarice Alegre Pretramale & Francisco de Assis Acurcio - 175-187 Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review
by Mo Zhou & Winter Maxwell Thayer & John F. P. Bridges - 189-204 Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
by Sergio Iannazzo & Ange-Christelle Iliza & Louise Perrault - 205-213 Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe
by Jonas Hermansson & Thomas Kahan - 215-223 Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
by Yasuhiro Hagiwara & Takeru Shiroiwa & Kojiro Shimozuma & Takuya Kawahara & Yukari Uemura & Takanori Watanabe & Naruto Taira & Takashi Fukuda & Yasuo Ohashi & Hirofumi Mukai - 225-238 Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
by Madeleine T. King & Rosalie Viney & A. Simon Pickard & Donna Rowen & Neil K. Aaronson & John E. Brazier & David Cella & Daniel S. J. Costa & Peter M. Fayers & Georg Kemmler & Helen McTaggart-Cowen & Rebecca Mercieca-Bebber & Stuart Peacock & Deborah J. Street & Tracey A. Young & Richard Norman - 239-252 Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System
by Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon - 253-257 Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?
by Melina Dritsaki & Alastair Gray & Stavros Petrou & Susan Dutton & Sarah E. Lamb & Joanna C. Thorn
January 2018, Volume 36, Issue 1
- 1-3 Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water
by Mattias Neyt - 5-6 Value-Based Pricing: L’Enfant Terrible?
by Sarah Garner & Andrew Rintoul & Suzanne R. Hill - 7-15 Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment
by Jaclyn Beca & Don Husereau & Kelvin K. W. Chan & Neil Hawkins & Jeffrey S. Hoch - 17-27 Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review
by Alisha Monnette & Yichen Zhang & Hui Shao & Lizheng Shi - 29-38 Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hazel Squires & Abdullah Pandor & Praveen Thokala & John W. Stevens & Eva Kaltenthaler & Mark Clowes & Robert Coleman & Lynda Wyld - 39-49 Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
by Irina A. Tikhonova & Tracey Jones-Hughes & James Dunham & Fiona C. Warren & Sophie Robinson & Peter Stephens & Martin Hoyle - 51-66 The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal
by Emma McManus & Tracey Sach & Nick Levell - 67-78 Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis
by Samuel Herzog & Marian Shanahan & Peter Grimison & Anh Tran & Nicole Wong & Nicholas Lintzeris & John Simes & Martin Stockler & Rachael L. Morton - 79-90 Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework
by Natalie Carvalho & Mark Jit & Sarah Cox & Joanne Yoong & Raymond C. W. Hutubessy - 91-103 Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
by Amir Ansaripour & Carin A. Uyl-de Groot & W. Ken Redekop - 105-113 Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
by Thea Asselt & Bram Ramaekers & Isaac Corro Ramos & Manuela Joore & Maiwenn Al & Ivonne Lesman-Leegte & Maarten Postma & Pepijn Vemer & Talitha Feenstra - 115-126 Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
by Usha G. Mallya & Susan H. Boklage & Andrew Koren & Thomas E. Delea & C. Daniel Mullins
December 2017, Volume 35, Issue 12
- 1195-1209 Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature
by Hamzeh Albaba & Charles Lim & Natasha B. Leighl - 1211-1221 Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nasuh C. Büyükkaramikli & Hedwig M. Blommestein & Rob Riemsma & Nigel Armstrong & Fiona. J. Clay & Janine Ross & Gill Worthy & Johan Severens & Jos Kleijnen & Maiwenn J. Al - 1223-1236 Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
by Jan Norum & Carsten Nieder - 1237-1255 Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice
by Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring - 1257-1270 Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
by Eddie Gibson & Ian Koblbauer & Najida Begum & George Dranitsaris & Danny Liew & Phil McEwan & Amir Abbas Tahami Monfared & Yong Yuan & Ariadna Juarez-Garcia & David Tyas & Michael Lees - 1271-1285 The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
by Alessandra Ferrario & Diāna Arāja & Tomasz Bochenek & Tarik Čatić & Dávid Dankó & Maria Dimitrova & Jurij Fürst & Ieva Greičiūtė-Kuprijanov & Iris Hoxha & Arianit Jakupi & Erki Laidmäe & Olga Löblová & Ileana Mardare & Vanda Markovic-Pekovic & Dmitry Meshkov & Tanja Novakovic & Guenka Petrova & Maciej Pomorski & Dominik Tomek & Luka Voncina & Alan Haycox & Panos Kanavos & Patricia Vella Bonanno & Brian Godman - 1287-1296 The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
by Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo - 1297-1310 Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety
by Mehdi Najafzadeh & Jorge A. Garces & Alejandra Maciel
November 2017, Volume 35, Issue 11
- 1111-1112 Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?
by Jonathan Karnon & Hossein Hajiali Afzali - 1113-1121 Replicating Health Economic Models: Firm Foundations or a House of Cards?
by Inigo Bermejo & Paul Tappenden & Ji-Hee Youn - 1123-1140 A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
by Hannah E. Burton & Stephen A. Mitchell & Maureen Watt - 1141-1151 Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Iñigo Bermejo & Matt Stevenson & Rachel Archer & John W. Stevens & Edward Goka & Mark Clowes & David L. Scott & Adam Young - 1153-1165 The Indonesian EQ-5D-5L Value Set
by Fredrick Dermawan Purba & Joke A. M. Hunfeld & Aulia Iskandarsyah & Titi Sahidah Fitriana & Sawitri Supardi Sadarjoen & Juan Manuel Ramos-Goñi & Jan Passchier & Jan J. V. Busschbach - 1167-1176 Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating
by Nicolas R. Thompson & Brittany R. Lapin & Irene L. Katzan - 1177-1185 Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer
by Laura McCullagh & Susanne Schmitz & Michael Barry & Cathal Walsh - 1187-1188 Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”
by Emma McManus & Tracey Sach - 1189-1190 Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’
by Inigo Bermejo & Paul Tappenden & Ji-Hee Youn
October 2017, Volume 35, Issue 10
- 977-980 ICER’s Revised Value Assessment Framework for 2017–2019: A Critique
by Peter J. Neumann & Joshua T. Cohen - 981-987 Availability and Pricing New Medicines in Ireland: Reflections and Reform
by Paul K. Gorecki - 989-1006 Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment
by Syed Salleh & Praveen Thokala & Alan Brennan & Ruby Hughes & Simon Dixon - 1007-1033 Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology
by Mohamed El Alili & Johanna M. Dongen & Judith A. F. Huirne & Maurits W. Tulder & Judith E. Bosmans - 1035-1046 Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & Adrian Bagust & Angela Boland & Sophie Beale & Marty Richardson & Ashma Krishan & Angela Stainthorpe & Ahmed Abdulla & Eleanor Kotas & Lindsay Banks & Miranda Payne - 1047-1062 Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
by Steven Simoens & Ira Jacobs & Robert Popovian & Leah Isakov & Lesley G. Shane - 1063-1072 Performance-Based Risk-Sharing Arrangements: An Updated International Review
by Josh J. Carlson & Shuxian Chen & Louis P. Garrison - 1073-1085 Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
by Eric Jutkowitz & Fernando Alarid-Escudero & Hyon K. Choi & Karen M. Kuntz & Hawre Jalal - 1087-1101 Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008–2012
by Abaigeal D. Jackson & Andrew L. Jackson & Godfrey Fletcher & Gerardine Doyle & Mary Harrington & Shijun Zhou & Fiona Cullinane & Charles Gallagher & Edward McKone - 1103-1109 Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code
by Jörgen Möller & Sarah Davis & Matt Stevenson & J. Jaime Caro
September 2017, Volume 35, Issue 9
- 859-866 Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?
by Caroline M. Vass & Katherine Payne - 867-877 Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties
by Laura Bojke & Bogdan Grigore & Dina Jankovic & Jaime Peters & Marta Soares & Ken Stein - 879-893 Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review
by Darío Rubio-Rodríguez & Silvia Diego Blanco & Maite Pérez & Carlos Rubio-Terrés - 895-908 Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors
by Susanne Mayer & Aggie T. G. Paulus & Agata Łaszewska & Judit Simon & Ruben M. W. A. Drost & Dirk Ruwaard & Silvia M. A. A. Evers - 909-919 Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Philip Morgan & Nerys Woolacott & Mousumi Biswas & Teumzghi Mebrahtu & Melissa Harden & Robert Hodgson - 921-936 The Cost of Relapse in Schizophrenia
by Mark Pennington & Paul McCrone - 937-949 Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews
by Syed Salleh & Praveen Thokala & Alan Brennan & Ruby Hughes & Andrew Booth - 951-962 Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling
by Howard Thom & Chris Jackson & Nicky Welton & Linda Sharples - 963-963 Erratum to: Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling
by Howard Thom & Chris Jackson & Nicky Welton & Linda Sharples - 965-974 Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss
by Ulrikke J. V. Hernæs & Kjell A. Johansson & Trygve Ottersen & Ole F. Norheim - 975-976 Ahead of Our Time: Collaboration in Modeling Then and Now
by Renée J. G. Arnold & Sean Ekins
August 2017, Volume 35, Issue 8
- 755-757 Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling
by Anthony J. Hatswell & Fleur Chandler - 759-765 Evaluation of Healthcare Interventions and Big Data: Review of Associated Data Issues
by Carl V. Asche & Brian Seal & Kristijan H. Kahler & Elisabeth M. Oehrlein & Meredith Greer Baumgartner - 767-776 How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis
by Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer - 777-791 Defining and Measuring the Affordability of New Medicines: A Systematic Review
by Fernando Antoñanzas & Robert Terkola & Paul M. Overton & Natalie Shalet & Maarten Postma - 793-804 Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics
by Liz Morrell & Sarah Wordsworth & Sian Rees & Richard Barker - 805-815 Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Christopher Carroll & John W. Stevens & Andrew Rawdin & Sabine Grimm & Mark Clowes & Eva Kaltenthaler & John R. Ingram & Fiona Collier & Mohammad Ghazavi - 817-830 A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models
by Chase Hollman & Mike Paulden & Petros Pechlivanoglou & Christopher McCabe - 831-844 Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
by Min Huang & Yanyan Lou & James Pellissier & Thomas Burke & Frank Xiaoqing Liu & Ruifeng Xu & Vamsidhar Velcheti - 845-858 Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
by James Buchanan & Sarah Wordsworth & Ruth Clifford & Pauline Robbe & Jenny C. Taylor & Anna Schuh & Samantha J. L. Knight
July 2017, Volume 35, Issue 7
- 669-672 Defining Value: The Need for a Longer, Broader View
by Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena - 673-683 Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview
by Erik J. Dasbach & Elamin H. Elbasha - 685-695 Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis
by Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins - 697-716 Discrete Choice Experiments: A Guide to Model Specification, Estimation and Software
by Emily Lancsar & Denzil G. Fiebig & Arne Risa Hole - 717-726 Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Lesley Uttley & Sophie Whyte & Timothy Gomersall & Shijie Ren & Ruth Wong & Duncan Chambers & Paul Tappenden - 727-740 Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
by Maarten J. IJzerman & Hendrik Koffijberg & Elisabeth Fenwick & Murray Krahn - 741-753 An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments
by Lidia Engel & Duncan Mortimer & Stirling Bryan & Scott A. Lear & David G. T. Whitehurst
June 2017, Volume 35, Issue 6
- 607-612 How Qualitative Methods Can be Used to Inform Model Development
by Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast - 613-624 Bayesian Methods for Calibrating Health Policy Models: A Tutorial
by Nicolas A. Menzies & Djøra I. Soeteman & Ankur Pandya & Jane J. Kim - 637-646 Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?
by Paul Mark Mitchell & Sridhar Venkatapuram & Jeff Richardson & Angelo Iezzi & Joanna Coast - 647-659 An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis
by Paul Tappenden & Susannah Sadler & Martin Wildman - 661-663 Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal”
by Odette Reifsnider & Fiona Hall & Sonja Sorensen & Irina Proskorovsky & Isabelle Girod & Jennifer Lee - 665-667 Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
by Bram L. T. Ramaekers & Rob Riemsma & Florian Tomini & Thea Asselt & Sohan Deshpande & Steven Duffy & Nigel Armstrong & Johan L. Severens & Jos Kleijnen & Manuela A. Joore
May 2017, Volume 35, Issue 5
- 493-500 Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?
by Alan Lyles - 501-515 Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review
by Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou - 517-535 Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review
by James Brockbank & Sorrel Wolowacz - 537-547 Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Christopher Carroll & Paul Tappenden & Rachid Rafia & Jean Hamilton & Duncan Chambers & Mark Clowes & Paul Durrington & Nadeem Qureshi & Anthony S. Wierzbicki - 549-559 Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland–Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data
by Jason Madan & Kamran A. Khan & Stavros Petrou & Sarah E. Lamb - 561-573 Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
by Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious - 575-589 The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling
by Asrul Akmal Shafie & Hui Yee Yeo & Laurent Coudeville & Lucas Steinberg & Balvinder Singh Gill & Rohani Jahis & Amar-Singh HSS - 591-601 Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland
by Paul Hanly & Rebecca Maguire & Myles Balfe & Eleanor O’Sullivan & Linda Sharp - 603-604 Comment on: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
by Afschin Gandjour - 605-606 Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”
by Monika Wagner & Mireille Goetghebeur
April 2017, Volume 35, Issue 4
- 397-413 Economic Studies in Motor Neurone Disease: A Systematic Methodological Review
by Alan Moore & Carolyn A. Young & Dyfrig A. Hughes - 415-424 Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Benjamin Kearns & Abdullah Pandor & Matt Stevenson & Jean Hamilton & Duncan Chambers & Mark Clowes & John Graham & M. Satish Kumar - 425-438 Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma
by Kelly Fust & Xiaoyan Li & Michael Maschio & Guillermo Villa & Anju Parthan & Richard Barron & Milton C. Weinstein & Luc Somers & Caroline Hoefkens & Gary H. Lyman - 439-451 Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
by Brendan Mulhern & Richard Norman & Paula Lorgelly & Emily Lancsar & Julie Ratcliffe & John Brazier & Rosalie Viney - 453-467 Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15
by Christine Mpundu-Kaambwa & Gang Chen & Remo Russo & Katherine Stevens & Karin Dam Petersen & Julie Ratcliffe - 469-478 Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US
by Renske J. Hoefman & Job Exel & Werner B. F. Brouwer - 479-491 A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
by C. Rinciog & M. Watkins & S. Chang & T. M. Maher & C. LeReun & D. Esser & A. Diamantopoulos
March 2017, Volume 35, Issue 3
- 259-269 Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis
by Henk Broekhuizen & Maarten J. IJzerman & A. Brett Hauber & Catharina G. M. Groothuis-Oudshoorn - 271-296 A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder
by Ifigeneia Mavranezouli & Joran Lokkerbol - 297-318 A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies
by Ching-Yun Wei & Ruben G. W. Quek & Guillermo Villa & Shravanthi R. Gandra & Carol A. Forbes & Steve Ryder & Nigel Armstrong & Sohan Deshpande & Steven Duffy & Jos Kleijnen & Peter Lindgren - 319-329 How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review
by Xinyang Hua & Thomas Wai-Chun Lung & Andrew Palmer & Lei Si & William H. Herman & Philip Clarke - 331-345 The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review
by Juan Oliva-Moreno & Marta Trapero-Bertran & Luz Maria Peña-Longobardo & Raúl del Pozo-Rubio - 347-362 Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence
by Richard Abreu Lourenco & Marion Haas & Jane Hall & Rosalie Viney - 363-373 Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
by Irina A. Tikhonova & Martin W. Hoyle & Tristan M. Snowsill & Chris Cooper & Joanna L. Varley-Campbell & Claudius E. Rudin & Ruben E. Mujica Mota - 375-396 Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
by Michael Willis & Pierre Johansen & Andreas Nilsson & Christian Asseburg
February 2017, Volume 35, Issue 2
- 129-139 Emergent Challenges in Determining Costs for Economic Evaluations
by Josephine C. Jacobs & Paul G. Barnett - 141-162 Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
by Asrul Akmal Shafie & Chin Hui Ng & Yui Ping Tan & Nathorn Chaiyakunapruk - 163-176 Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy
by Anthony J. Hatswell & Nick Freemantle & Gianluca Baio - 177-190 Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update
by Spencer M. Vale & Dane Hill & Steven R. Feldman - 191-202 Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Rob Riemsma & Florian Tomini & Thea Asselt & Sohan Deshpande & Steven Duffy & Nigel Armstrong & Johan L. Severens & Jos Kleijnen & Manuela A. Joore - 203-213 A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
by Ros Wade & Robert Hodgson & Mousumi Biswas & Melissa Harden & Nerys Woolacott - 215-223 A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016
by Jacquelyn McRae & F. Randy Vogenberg & Silky Webb Beaty & Elizabeth Mearns & Stefan Varga & Laura Pizzi - 225-235 Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK
by Richard Lawson & James Ryan & Frederic King & Jo Wern Goh & Eszter Tichy & Kevin Marsh - 237-248 Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
by Lindsay Claxton & Robert Hodgson & Matthew Taylor & Bill Malcolm & Ruth Pulikottil Jacob - 249-258 Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
by Erik Landfeldt & Lars Alfredsson & Volker Straub & Hanns Lochmüller & Katharine Bushby & Peter Lindgren
December 2017, Volume 35, Issue 1
- 1-3 Heath State Utility Values for Cost-Effectiveness Models
by Jonathan Karnon - 5-6 Special Edition on Utility Measurement, PharmacoEconomics
by Andrew Lloyd - 7-9 Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care
by Roberta Ara & Tessa Peasgood & Clara Mukuria & Helene Chevrou-Severac & Donna Rowen & Ismail Azzabi-Zouraq & Suzy Paisley & Tracey Young & Ben Hout & John Brazier - 11-19 International Regulations and Recommendations for Utility Data for Health Technology Assessment
by Donna Rowen & Ismail Azzabi Zouraq & Helene Chevrou-Severac & Ben Hout - 21-31 A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models
by John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac - 33-41 The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment
by Donna Rowen & John Brazier & Roberta Ara & Ismail Azzabi Zouraq - 43-55 The Identification, Review and Synthesis of Health State Utility Values from the Literature
by Roberta Ara & John Brazier & Tessa Peasgood & Suzy Paisley - 57-66 The Use of Mapping to Estimate Health State Utility Values
by Roberta Ara & Donna Rowen & Clara Mukuria - 67-75 Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies
by Roberta Ara & John Brazier & Tracey Young - 77-88 The Use of Health State Utility Values in Decision Models
by Roberta Ara & John Brazier & Ismail Azzabi Zouraq - 89-94 Estimating Health State Utility Values for Comorbidities
by Roberta Ara & John Brazier
January 2017, Volume 35, Issue 1
- 1-4 Measuring the Value of Pharmaceuticals in the US Health System
by Surrey M. Walton & Anirban Basu & John Mullahy & Samuel Hong & Glen T. Schumock - 5-13 Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
by Mike Paulden & James F. O’Mahony & Christopher McCabe - 15-24 Modeling Treatment Sequences in Pharmacoeconomic Models
by Ying Zheng & Feng Pan & Sonja Sorensen - 25-42 The Societal Cost of Schizophrenia: A Systematic Review
by Huajie Jin & Iris Mosweu - 43-63 Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations
by Simon van der Schans & Lucas M. A. Goossens & Melinde R. S. Boland & Janwillem W. H. Kocks & Maarten J. Postma & Job F. M. van Boven & Maureen P. M. H. Rutten-van Mölken - 65-82 Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations
by Obinna I. Ekwunife & James F. O’Mahony & Andreas Gerber Grote & Christoph Mosch & Tatjana Paeck & Stefan K. Lhachimi - 83-95 Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review
by Mahdi Gharaibeh & J. Lyle Bootman & Ali McBride & Jennifer Martin & Ivo Abraham - 97-109 Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Sue Harnan & Shijie Ren & Praveen Thokala & Ruth Wong & Clara Mukuria & Clare Green & Simon Pledge & John Tidy - 111-124 Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)
by Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson - 125-128 Benefits, Challenges and Potential Strategies of Open Source Health Economic Models
by William C. N. Dunlop & Nicola Mason & James Kenworthy & Ron L. Akehurst
December 2016, Volume 34, Issue 12
- 1195-1209 Using Best–Worst Scaling to Investigate Preferences in Health Care
by Kei Long Cheung & Ben F. M. Wijnen & Ilene L. Hollin & Ellen M. Janssen & John F. Bridges & Silvia M. A. A. Evers & Mickael Hiligsmann - 1211-1225 Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review
by Surasak Saokaew & Ajaree Rayanakorn & David Bin-Chia Wu & Nathorn Chaiyakunapruk - 1227-1239 The Value of Medicines: A Crucial but Vague Concept
by Fernando Antoñanzas & Robert Terkola & Maarten Postma - 1241-1253 Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachid Rafia & Alison Scope & Sue Harnan & John W. Stevens & Matt Stevenson & Alan Lobo - 1255-1265 Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study
by Pei-Jung Lin & Cayla J. Saret & Peter J. Neumann & Eileen A. Sandberg & Joshua T. Cohen - 1267-1276 The Pharmacoeconomic Evaluation Process in Ireland
by Laura McCullagh & Michael Barry - 1277-1297 Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases
by Paul S. J. Miller & Harry Hill & Fredrik L. Andersson - 1299-1308 Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
by Christiaan Dolk & Martin Eichner & Robert Welte & Anastassia Anastassopoulou & Laure-Anne Van Bellinghen & Barbara Poulsen Nautrup & Ilse Van Vlaenderen & Ruprecht Schmidt-Ott & Markus Schwehm & Maarten Postma
November 2016, Volume 34, Issue 11
- 1071-1074 From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare
by Matthijs Versteegh & Saskia Knies & Werner Brouwer - 1075-1086 Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation
by Padraig Dixon & George Davey Smith & Stephanie von Hinke & Neil M. Davies & William Hollingworth - 1087-1100 Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies
by Feng Xie & Bruno Kovic & Xuejing Jin & Xiaoning He & Mengxiao Wang & Camila Silvestre - 1101-1110 The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
by Eleftherios Sideris & Mark Corbett & Stephen Palmer & Nerys Woolacott & Laura Bojke - 1111-1131 A Methodological Review of US Budget-Impact Models for New Drugs
by Josephine Mauskopf & Stephanie Earnshaw - 1133-1144 Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
by Matthijs Versteegh - 1145-1159 Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
by Jamie Elvidge & Ash Bullement & Anthony J. Hatswell - 1161-1172 Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations
by Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne - 1173-1186 Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience
by François Bocquet & Anaïs Loubière & Isabelle Fusier & Anne-Laure Cordonnier & Pascal Paubel - 1187-1188 Discretely Integrated Condition Event Simulation for Pharmacoeconomics
by Mondher Toumi & Ekkehard Beck & Steve Sherman & Leyla Mohseninejad & Samuel Aballéa - 1189-1190 Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics
by J. Jaime Caro
October 2016, Volume 34, Issue 10
- 967-969 Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?
by Livio Garattini & Alessandro Curto - 971-980 Sustainable Financing of Innovative Therapies: A Review of Approaches
by Aidan Hollis - 981-992 Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence
by Alexis Llewellyn & Rita Faria & Beth Woods & Mark Simmonds & James Lomas & Nerys Woolacott & Susan Griffin - 993-1004 EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes
by Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo - 1005-1014 The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan
by Haruhisa Fukuda & Shunya Ikeda & Takeru Shiroiwa & Takashi Fukuda - 1015-1022 Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3
by Ron D. Hays & Dennis A. Revicki & David Feeny & Peter Fayers & Karen L. Spritzer & David Cella - 1023-1038 A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
by Paul Tappenden & Shijie Ren & Rachel Archer & Rebecca Harvey & Marrissa Martyn-St James & Hasan Basarir & John Stevens & Alan Lobo & Sami Hoque - 1039-1050 Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
by Bonny Parkinson & Rosalie Viney & Marion Haas & Stephen Goodall & Preeyaporn Srasuebkul & Sallie-Anne Pearson - 1051-1065 BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
by William C. N. Dunlop & C. Daniel Mullins & Olaf Pirk & Ron Goeree & Maarten J. Postma & Ashley Enstone & Louise Heron - 1067-1070 Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?
by T. Joseph Mattingly & C. Daniel Mullins & Eberechukwu Onukwugha
September 2016, Volume 34, Issue 9
- 829-831 Model Validation: Has it’s Time Come?
by Jonathan Karnon - 833-845 Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
by Pieter T. Boer & Geert W. J. Frederix & Talitha L. Feenstra & Pepijn Vemer - 847-861 Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches
by Joshua Pink & Ben Parker & Stavros Petrou - 901-912 The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence
by James Lomas & Alexis Llewellyn & Marta Soares & Mark Simmonds & Kath Wright & Alison Eastwood & Stephen Palmer - 913-923 Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial
by Stéphane Verguet & Jane J. Kim & Dean T. Jamison - 925-937 Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland
by Susanne Schmitz & Laura McCullagh & Roisin Adams & Michael Barry & Cathal Walsh - 939-951 The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
by Lisa Nagy & Terho Heikkinen & Alfred Sackeyfio & Richard Pitman - 953-966 Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
by Melanie J. Davies & Divina Glah & Barrie Chubb & Gerasimos Konidaris & Phil McEwan
August 2016, Volume 34, Issue 8
- 723-731 Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges
by Sevan Dirmesropian & James G. Wood & C. Raina MacIntyre & Philippe Beutels & Anthony T. Newall - 741-750 Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective
by P. Thokala & E. L. Simpson & P. Tappenden & J. W. Stevens & K. Dickinson & S. Ryder & P. Harrison - 805-814 The Impact of Different DCE-Based Approaches When Anchoring Utility Scores
by Richard Norman & Brendan Mulhern & Rosalie Viney - 815-827 Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
by Jonathan Graham & Doreen McBride & Donald Stull & Anna Halliday & Stamatia Theodora Alexopoulos & Maria-Magdalena Balp & Matthew Griffiths & Ion Agirrezabal & Torsten Zuberbier & Alan Brennan
July 2016, Volume 34, Issue 7
- 625-627 Why Cancer?
by Alan Haycox - 635-644 Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine
by Gregory S. Zaric - 645-649 Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?
by Milad Karimi & John Brazier - 651-664 Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches
by James Shearer & Paul McCrone & Renee Romeo